Dr. Mehmet Oz Confirmed as Head of Centers for Medicare & Medicaid Services
The U.S. Senate has confirmed Dr. Mehmet Oz as the new head of the Centers for Medicare & Medicaid Services (CMS) in a 53-45 vote along party lines.
Latigo Secures $150M Series B to Advance Non-Opioid Pain Medications Through Late-Stage Trials
Latigo Biotherapeutics has raised $150 million in Series B funding led by Blue Owl Capital to advance its pipeline of non-opioid pain medications targeting NaV1.8 and other pain pathways.
Major Insurers and PBMs Control 34% of Medicare Part D Pharmacy Spending, Study Reveals
A comprehensive analysis of Medicare Part D claims reveals that CVS, Humana, Cigna, and UnitedHealth Group control 34.1% of all pharmacy spending, with even higher shares in specialty pharmacy segments.
Biosimilar Updates: Trastuzumab, Adalimumab, Ustekinumab, and Aflibercept
The FDA approved a higher 420mg strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin, for HER2-positive breast and gastric cancers, expanding treatment options.
© Copyright 2025. All Rights Reserved by MedPath